← The SEC Ephemeris: the whole map
Orphazyme A/S arimoclomol
In the graph: all 1 documents (7 pages).
- Application
- NDA 214927
- Ticker
- Orphazyme A/S
- Product
- arimoclomol
- Disease area
- Not yet classified
- Response path
- Not yet classified
- Complete Response Letters
- June 17, 2021
From FDA letters and SEC filings. Not investment or medical advice.